BioSpace News Archive

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts featuring data on oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) at the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, which is being held in San Antonio, Texas, from February 24-27, 2023.

Tonix Pharmaceuticals Holding Corp. today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will participate virtually in the BIO CEO & Investor Conference, which is being held February 6-9, 2023.

Celldex Therapeutics, Inc. announced today that data from the Company’s Phase 1b multi-dose study of barzolvolimab in chronic spontaneous urticaria will be presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023 being held February 24-27 in San Antonio, Texas.

Azenta, Inc. (Nasdaq: AZTA) today announced that it has acquired Ziath, Ltd. and its subsidiaries (“Ziath”). Based in Cambridge, UK, Ziath is a leading provider of 2D barcode readers for life sciences applications.

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023.

Oragenics, Inc. today announced that the Company has received formal notice from the NYSE American, LLC (“NYSE American”) stating that the Company has regained compliance with the NYSE American’s continued listing standards.

The Association of Diversity in Clinical Trials (AOD) is being launched and introduced at upcoming industry conferences SCOPE and the Health Equity in Clinical Trials Congress this month.

Insmed Incorporated today announced the granting of inducement awards to 18 new employees.

Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology.

Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.